Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/17/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Stephan A. Grupp

Wrong Dr. Stephan A. Grupp?

Fellowship Director

Local Address: PHILADELPHIA, Pennsylvania, United States
The Children's Hospital of Philadelphia
34 Civic Center Blvd.
Philadelphia , Pennsylvania 19104
United States

Company Description: About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
  • PhD
  • M.D.
    University of Pennsylvania
  • Ph.D.
139 Total References
Web References
That's amazing," said senior researcher ...
westhillssurgicalcenter.com, 16 Oct 2014 [cached]
That's amazing," said senior researcher Dr. Stephan Grupp, of Children's Hospital of Philadelphia and the University of Pennsylvania.
...
But, both Grupp and Sadelain said ongoing studies will have to clarify the therapy's role in treating ALL.
...
A major question now, Grupp said, is whether the cell therapy, alone, can keep ALL patients in remission.
...
Grupp called that an "encouraging" sign that cell therapy could be a stand-alone treatment. "But we are not there yet," he stressed.
As for safety, Grupp said the major short-term risk is cytokine release syndrome -- which causes symptoms including persistent fever, a drop in blood pressure and difficulty breathing. All of the patients in the current trial had cytokine release syndrome soon after treatment, according to the study. No one died as a result of this therapy, however.
"Patients can get quite sick," Grupp said, "but it's a manageable side effect."
In July, the U.S. Food and Drug Administration granted the cell therapy a "breakthrough therapy" designation for advanced ALL -- which could speed the treatment through the standard regulatory review process, according to the researchers.
Drug company Novartis, which partially funded this study, has licensed the particular technology used in the current study and is doing a larger trial at multiple U.S. hospitals; Grupp and some of his co-researchers are inventors of the technology and stand to financially benefit.
...
This treatment is still restricted to the research setting, but Grupp said patients with relapsed ALL can ask their doctors about the possibility of enrolling in a trial.
More information
The American Cancer Society has more on acute lymphoblastic leukemia (http://www.cancer.org/cancer/leukemia-acutelymphocyticallinadults/detailedguide/leukemia-acute-lymphocytic-what-is-all ).
SOURCES: Stephan Grupp, M.D., Ph.D., director, translational research, Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Michel Sadelain, M.D., Ph.D., director, Center for Cell Engineering, Memorial-Sloan Kettering Cancer Center, New York City; Oct. 16, 2014, New England Journal of Medicine
"We're seeing pediatric patients who ...
www.santelog.com, 6 Dec 2014 [cached]
"We're seeing pediatric patients who have not responded to any other therapy achieve complete remission as a result of treatment with CTL019," said lead investigator Stephan Grupp, MD, PhD, the Yetta Deitch Novotny Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia (CHOP).
...
[1] Grupp, Stephan A. et al. (8 December 2014). T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 380 [2] Maude S et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014; 371:1507-17. [3] Schuster, Stephen J. et al. (7 December 2014). Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 3087 [4] Frey, Noelle V. et al. (7 December 2014). Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 2296 [5] Porter, David L. et al. (6 December 2014). Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 1982 [6] Porter, David L. et al. (6 December 2014). Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 1983 [7] Bhoj, Vijay et al. (6 December 2014). Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 1110 [8] Ruella, Marco et al. (6 December 2014). Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 966 [9] Ruella, Marco et al. (9 December 2014). Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 806 [10] Kawalekar, Omkar U. et al. (8 December 2014). Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 551 [11] Posey, Avery D. et al. (8 December 2014). Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia [oral presentation]. 2014 American Society of Hematology Meeting and Exposition: Abstract 4803 [12] US Food and Drug Administration. Guidance for Industry Expedited Programs for Serious Conditions - Drugs and Biologics Frequently Asked Questions: Breakthrough Therapies. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf . Accessed November 2014. [13] Howlader, N., Noone, A. M., Krapcho, M, et al. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute, April 2013; Section 28.9 (12). http://www.seer.cancer.gov/csr/1975_2010/results_merged/sect_28_childhood_cancer.pdf . Accessed June 2014. [14] Apostolidou, Effrosyni, et al. Treatment of Acute Lymphoblastic Leukaemia. Drugs 2007; 67 (15): 2153-2171.
The study's senior author, Stephan ...
www.raredr.com, 31 Oct 2014 [cached]
The study's senior author, Stephan Grupp, MD, PhD, a professor of Pediatrics in Penn's Perelman School of Medicine and director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia said:
Board of Trustees | Aspho.org
www.aspho.org, 13 Feb 2014 [cached]
Stephan Grupp, MD PhD Children's Hospital of Philadelphia
Children’s Neuroblastoma Cancer Foundation Medical Advisory Board | CNCF
www.cncfhope.org, 9 Aug 2014 [cached]
Stephan Grupp, MD Children's Hospital of Philadelphia
Other People with the name "Grupp":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304